Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Intangibles: 2013-2025

Historic Change in Intangibles for Ani Pharmaceuticals (ANIP) over the last 6 years, with Sep 2025 value amounting to $60,000.

  • Ani Pharmaceuticals' Change in Intangibles fell 90.49% to $60,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 98.76%. This contributed to the annual value of $717,000 for FY2024, which is 92.56% down from last year.
  • Ani Pharmaceuticals' Change in Intangibles amounted to $60,000 in Q3 2025, which was down 97.93% from $2.9 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Change in Intangibles peaked at $21.0 million during Q2 2021, and registered a low of $4,000 during Q4 2022.
  • Its 3-year average for Change in Intangibles is $3.4 million, with a median of $2.5 million in 2023.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Change in Intangibles slumped by 99.93% in 2021, and later skyrocketed by 62,400.00% in 2023.
  • Over the past 5 years, Ani Pharmaceuticals' Change in Intangibles (Quarterly) stood at $12,000 in 2021, then plummeted by 66.67% to $4,000 in 2022, then skyrocketed by 62,400.00% to $2.5 million in 2023, then slumped by 96.56% to $86,000 in 2024, then plummeted by 90.49% to $60,000 in 2025.
  • Its Change in Intangibles was $60,000 in Q3 2025, compared to $2.9 million in Q2 2025 and $17.4 million in Q1 2025.